News Verdiva Bio raises $411m for obesity pipeline A new obesity startup – Verdiva Bio – has just decloaked with a whopping $411m to advance a once-weekly oral GLP-1 agonist.
News Amid sector disruption, biotech must focus on 'fundamentals'... The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
